Resources

This study systemically reviewed randomized controlled trials and observational studies to evaluate whether actual exposure of metformin can be associated with cancer and cancer mortality in type 2 diabetes patients….

Women diagnosed with Polycystic Ovary Syndrome are at an increased risk of type 2 diabetes and cardiovascular disease….

Promising results from IDegLira and the DUAL I trial…. Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection. In the Dual Action of Liraglutide and Insulin …

GLP-1 agonist may prove beneficial to type 1 diabetes….

The cost of treating a type 2 diabetes patient throughout their lifetime is estimated to be $85,500….

Diabetes and end stage renal disease (ESRD), when together, contribute to increased cardiovascular (CV) events, such as acute myocardial infarction and stroke….

Do metabolically healthy obese individuals have higher risks for diabetes and CVD?…

How does diet, alcohol consumption, and sodium intake affect incidence or progression of CKD in diabetic patients?…

Here’s out most recent list of insurance covereage. The cash price for 1 month of Invokana is $315.72. Current actual coverage is: RXE United and other discount cards are approximately $268. PSN Commercial calls it non-formulary and charges a $100 co-pay. AARP-United Health will allow the first fill with a $95 …

We hear a lot from clinicians about new drugs but we don’t always get the patient perspective until much later. Invokana (canagliflozin) has been available for several months now, though, so we spoke with a few patients to find out what their experience has been so far: "I was on …